spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  fast track designation 


 Your search returned too many results! The most recent 500 items are shown below:
 HSMN NewsFeed - 3 Oct 2024
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Sep 2024
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 9 Aug 2024
FDA Approves First Nasal Spray for Treatment of Anaphylaxis
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 29 Jul 2024
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Apr 2024
Sobi(R) Receives Positive CHMP Opinion Recommending Approval of Efanesoctocog Alfa for Once-Weekly Treatment of Haemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Apr 2024
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS(R) (edaravone)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Mar 2024
Renibus Announces Leadership Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate (ADC) Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Jan 2024
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 13 Dec 2023
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2023
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101(TM) for Chronic Pain
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jan 2023
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
Regenerative Medicine Ophthalmology FDA
 HSMN NewsFeed - 23 Jan 2023
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2023
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Nov 2022
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 26 Sep 2022
Innocoll and DURECT Announce U.S. launch of POSIMIR(R)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 11 Jul 2022
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2022
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 31 May 2022
Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Mar 2022
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 6 Dec 2021
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2021
Kintara Announces Changes to Executive Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jul 2021
BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 29 Jun 2021
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2021
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2021
Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Feb 2021
DURECT Corporation Announces U.S. FDA Approval of POSIMIR(R) For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 5 Jan 2021
DURECT Corporation Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 30 Dec 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2020
Lilly Announces Agreement to Acquire Prevail Therapeutics
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 30 Nov 2020
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2020
FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 2 Oct 2020
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Sep 2020
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 24 Sep 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2020
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 28 Jul 2020
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2020
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 26 Jun 2020
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2020
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jun 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 May 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 May 2020
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 May 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Mar 2020
Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 10 Jan 2020
Lilly Announces Agreement to Acquire Dermira
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 18 Nov 2019
Levo Therapeutics Receives Fast Track Designation From FDA for Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 18 Nov 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Nov 2019
Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Nov 2019
EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 25 Oct 2019
Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: Pravibismane
Biopharmaceuticals Generics
 HSMN NewsFeed - 23 Oct 2019
NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Aug 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jul 2019
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 May 2019
Rakuten Medical Opens Two New Offices In The Netherlands And Taiwan, Adding New Jobs To Strengthen And Expand Its Global Presence
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2019
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
Diagnostics Oncology
 HSMN NewsFeed - 8 May 2019
ReNeuron Provides Business Update and Results Notification
Regenerative Medicine Ophthalmology Neurology
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Apr 2019
Neurelis Announces Completion of Senior Management Team Buildout to Support the Anticipated Commercial Launch of VALTOCO(TM)
Biopharmaceuticals Drug Delivery Neurology Personnel
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Mar 2019
Enzyvant's Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2019
RDD Pharma Appoints John Temperato as Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 1 Mar 2019
Rakuten Aspyrian Announces Name Change to Rakuten Medical
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Dec 2018
FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 21 Dec 2018
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 19 Nov 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2018
Aronora's New Blood Clot Treatment Receives FDA Fast Track Designation
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Sep 2018
Neurelis Files New Drug Application with the FDA for VALTOCO(TM) Nasal Spray, an Investigational Treatment for Pediatric, Adolescent and Adult Epilepsy Patients
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 12 Sep 2018
Biohaven Appoints Bob Repella to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 Aug 2018
Anchiano Therapeutics Appoints Efrat Makov to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2018
Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Aug 2018
Rakuten Aspyrian Raises $150 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Aug 2018
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jul 2018
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jul 2018
Adlai Nortye Raises $53M in Series B
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 31 May 2018
Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 May 2018
TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten(R) for the Treatment of Intradialytic Hypotension
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 May 2018
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 May 2018
Ansun BioPharma secures $85 million in Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2018
Aptinyx Promotes David Houck to Chief Development Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 1 May 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Apr 2018
FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 4 Apr 2018
Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Feb 2018
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2018
Galmed Announces ARRIVE Study Data
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2018
Aptinyx Appoints Ashish Khanna Chief Financial Officer and Chief Business Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Jan 2018
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 28 Dec 2017
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Dec 2017
NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Dec 2017
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Dec 2017
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2017
Aptinyx Bolsters Executive Leadership Team with Appointment of Andy Kidd as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Nov 2017
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2017
NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 27 Jul 2017
Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2017
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 May 2017
Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 May 2017
Oncolytics Biotech(R) Inc. Announces FDA Fast Track Designation for REOLYSIN(R) in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Apr 2017
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Apr 2017
Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Apr 2017
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2017
aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jan 2017
ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jan 2017
Zogenix Announces CFO Transition
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Dec 2016
Grünenthal Receives Breakthrough Therapy Designation From U.S. FDA for Neridronic Acid for the Treatment of CRPS
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Dec 2016
Celldex Therapeutics Announces Appointment to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2016
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics’ Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Nov 2016
FDA Grants Fast Track Designation for Development of E2609, Eisai's BACE Inhibitor for Early Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Nov 2016
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2016
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Oct 2016
aTyr Pharma Receives FDA Fast Track Designation for Resolaris(TM) to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2016
SELLAS(TM) Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Oct 2016
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Sep 2016
Sanaria(R) PfSPZ Vaccine Against Malaria Receives FDA Fast Track Designation
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2016
Aptinyx Receives FDA Fast Track Designation for Development of NYX-2925 as Treatment for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Sep 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Sep 2016
FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen(R) Depot IND Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Aug 2016
Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Aug 2016
DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jul 2016
Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 28 Jul 2016
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2016
US FDA pathway opens to SCENESSE(R) following Fast Track designation for treatment of EPP
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2016
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2016
Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 May 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Biopharmaceuticals
 HSMN NewsFeed - 3 May 2016
XBiotech Appoints Amgen Veteran Scott Whitehurst as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Apr 2016
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Apr 2016
European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix(TM), XBiotech’s True Human(TM) Therapeutic Antibody Treatment for Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Feb 2016
TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Feb 2016
Emmaus Life Sciences Announces Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2016
Proteostasis Therapeutics Receives FDA Fast Track Designation for PTI-428 in Patients With Cystic Fibrosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2016
Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Jan 2016
Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Dec 2015
Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2015
Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 Nov 2015
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2015
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
Biopharmaceuticals
 HSMN NewsFeed - 24 Sep 2015
Cerulean Appoints David R. Walt, Ph.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jun 2015
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 12 May 2015
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2015
Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 2 Apr 2015
Perosphere Receives FDA Fast Track Designation for Investigational Anticoagulant Reversal Agent PER977
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Mar 2015
VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Oct 2014
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
Biopharmaceuticals Devices Cardiology Acquisitions
 HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Fast Track Designation for HT-100 from FDA for the Treatment of Duchenne Muscular Dystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2014
Prima BioMed's CVac(TM) Granted Fast Track Designation by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Apr 2014
Chimerix Announces Appointment of M. Michelle Berrey, M.D., M.P.H. as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2014
Immune CEO Announces New Operational Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2014
Chimerix Appoints Lisa Ricciardi to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Mar 2014
FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Mar 2014
PaxVax Announces New Commercial Senior Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2014
KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2014
Navidea Biopharmaceuticals Expands Lymphoseek(R) Global Commercialization Efforts
Biopharmaceuticals Radiology Distribution
 HSMN NewsFeed - 6 Jan 2014
Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Dec 2013
Chimerix Appoints Linda M. Richardson as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2013
FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek(R) for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 4 Dec 2013
PaxVax Secures $22 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2013
Defibrotide Granted Orphan Drug Status in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Oct 2013
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
Biopharmaceuticals Regulatory Product Launch
 HSMN NewsFeed - 2 Oct 2013
Salvatore Calabrese Appointed to Chief Operating Officer at Gentium S.p.A.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Aug 2013
KaloBios Appoints V. Bryan Lawlis, Jr., Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2013
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Feb 2013
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Feb 2013
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Feb 2013
Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna(TM) (imilecleucel-T) for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 29 Jan 2013
FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jan 2013
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 24 Jan 2013
Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury
Biopharmaceuticals Neurology Neurosurgery
 HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2012
Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2012
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Oct 2012
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Oct 2012
Sunesis Pharmaceuticals Announces Management Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Sep 2012
Sarepta Therapeutics' Lead Therapeutic Drugs for Ebola and Marburg Viruses Receive FDA Fast Track Designation
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Sep 2012
Alvine Pharmaceuticals’ ALV003 Receives Fast Track Designation From the FDA for the Potential Treatment of Celiac Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Aug 2012
Tokai Pharmaceuticals Appoints Adrian M. Senderowicz, M.D., as Chief Medical Officer and Vice President, Medical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2012
Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 May 2012
Talon Therapeutics Appoints Head of Commercial Operations and Planning
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 2 May 2012
Gentium Appoints PharmaSwiss, S.A. as Exclusive Distributor of Defibrotide in Central and Eastern European Countries
Biopharmaceuticals Distribution
 HSMN NewsFeed - 11 Apr 2012
MacuCLEAR, Inc. To Begin Phase III Study of its Lead Compound for Early-Stage Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Apr 2012
AlloCure Raises $25 Million Series B Venture Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Feb 2012
The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2012
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet(TM) Phase III CIPN Program and Regulatory Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jan 2012
Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Dec 2011
Gentium Provides Update on MAA Process for Defibrotide in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Oct 2011
Phase III Trial of Bayer's Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Aug 2011
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada(TM)*) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jun 2011
Repligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2011
Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Mar 2011
Gentium Appoints Adrian Haigh as Senior Vice President of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2011
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Feb 2011
Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Feb 2011
Sunesis Receives FDA Fast Track Designation for Vosaroxin in AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Feb 2011
Pervasis Receives FDA Fast Track Status for Vascugel(R) to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Biopharmaceuticals Interventional FDA
 HSMN NewsFeed - 24 Jan 2011
Furiex Receives FDA Fast Track Designation of MuDelta for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 19 Jan 2011
Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Dec 2010
Bavarian Nordic Receives Special Protocol Assessment Agreement From the FDA for Phase 3 Trial of PROSTVAC(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Sep 2010
Pfizer to Acquire FoldRx Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Aug 2010
Celsion Receives Fast Track Designation for ThermoDox(R) Development Program to Treat Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 14 Jul 2010
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 May 2010
Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging
Biopharmaceuticals Radiology
 HSMN NewsFeed - 18 May 2010
Dr. Henry A. McKinnell Jr., Former Pfizer CEO, Joins Emmaus Medical, Inc. Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2010
Bavarian Nordic Receives FDA Fast Track Designation for PROSTVAC(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2010
Gentium Announces Management Changes and Corporate Restructuring
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Feb 2010
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2010
New Scientific Publication Highlights Long-Term Survival of Brain Cancer Patients Treated With Peregrine Pharmaceuticals' Cotara(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2010
PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2010
IRX Therapeutics Appoints Neil L. Berinstein Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2010
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Dec 2009
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2009
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 2 Dec 2009
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Nov 2009
ARCA Receives FDA Fast Track Designation for Gencaro(TM) Development in Genotype-Defined Heart Failure Population
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Nov 2009
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Oct 2009
Lux Biosciences Completes $50 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 8 Sep 2009
FDA Grants Protalix Orphan Drug Designation for prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2009
Protalix Receives FDA Fast Track Designation for prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Aug 2009
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Biopharmaceuticals
 HSMN NewsFeed - 3 Aug 2009
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jul 2009
FDA Designates Fast Track Status for Apaziquone (EOquin(R)) for Bladder Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2009
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jul 2009
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Jul 2009
Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2009
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2009
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2009
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2009
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Mar 2009
Molecular Insight Receives Special Protocol Assessment Approval From FDA for Phase 2 Trial of Azedra(TM), a Radiotherapeutic to Treat Neuroendocrine Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Feb 2009
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Feb 2009
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Feb 2009
Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Fast Track Designation From FDA for Therapy of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jan 2009
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2009
Merck Serono's Oral Investigational Treatment Cladribine Tablets for Multiple Sclerosis Significantly Reduced Relapse Rate in Two-Year Phase III Pivotal Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Jan 2009
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
Regenerative Medicine FDA
 HSMN NewsFeed - 6 Jan 2009
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
Biopharmaceuticals
 HSMN NewsFeed - 3 Dec 2008
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2008
Innocoll Receives Fast Track Designation for Gentamicin Surgical Implant
Devices Drug Delivery FDA
 HSMN NewsFeed - 11 Nov 2008
TNFerade(TM) Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Oct 2008
HepaLife(TM) Acquires Liver Support Technology, Tested in America's Largest-Ever Human Clinical Trial for Bioartificial Liver Assist Devices
Devices Acquisitions
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Sep 2008
Proteon Receives FDA Fast Track Designation for First Drug Candidate PRT-201
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Sep 2008
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 3 Sep 2008
Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications - Retinitis Pigmentosa and Dry Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 7 Aug 2008
Dyax Corp. Announces the Appointment of George Migausky as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2008
Collegium Pharmaceutical Announces Completion of Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jul 2008
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jun 2008
IRX Therapeutics Names Scott M. Freeman, M.D. Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Jun 2008
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2008
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2008
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 May 2008
Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2008
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
Biopharmaceuticals
 HSMN NewsFeed - 8 Apr 2008
Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Mar 2008
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2008
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Feb 2008
FDA Accepts for Review OVATION's Two NDA Submissions for Sabril(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Feb 2008
Solvay Pharmaceuticals, Inc. Receives Fast Track Designation From U.S. Food and Drug Administration for Levodopa/Carbidopa Intestinal Gel for Advanced Parkinson's Disease
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 13 Feb 2008
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2008
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
Biopharmaceuticals Ophthalmology Drug Delivery FDA
 HSMN NewsFeed - 28 Jan 2008
Synta and GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation by the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jan 2008
Carol R. Epstein, M.D. Joins IRX Therapeutics As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2008
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Dec 2007
CytRx Announces Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2007
Neurologix Gene Therapy Approach to Parkinson's Disease Granted Fast Track Designation From FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Dec 2007
Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
Biopharmaceuticals Neurology Interventional
 HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
GTC Obtains FDA Orphan Drug Designation For ATryn(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 8 Dec 2007
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2007
Medicure Announces Appointment to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2007
Dyax Announces Plans for Retirement of Steve Galliker as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2007
Lev Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2007
Protox collaborates with BrainLAB for Brain Cancer Program
Devices Neurosurgery
 HSMN NewsFeed - 2 Nov 2007
Progen Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Oct 2007
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2007
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Oct 2007
Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Oct 2007
GlaxoSmithKline and Synta Pharmaceuticals Announce Development and Commercialization Collaboration for STA-4783 in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2007
Declan P. Doogan, M.D. Joins IRX Therapeutics as Advisor on Global Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2007
Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Sep 2007
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 24 Sep 2007
CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
Biopharmaceuticals Neurology Wound Care
 HSMN NewsFeed - 24 Sep 2007
US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2007
Medicure Announces Completion of Enrollment in Pivotal Phase 3 MEND-CABG II Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 Sep 2007
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Sep 2007
CytRx Names Mitchell K. Fogelman Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 6 Sep 2007
CytRx Subsidiary RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Sep 2007
Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 5 Sep 2007
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
GTC Obtains FDA Fast Track Designation for ATryn(R) and Permission to Submit a Rolling BLA
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Sep 2007
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 29 Aug 2007
Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 22 Aug 2007
Hana Biosciences Receives Fast Track Designation for Marqibo for the Treatment of Relapsed Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
Bioniche Provides Update on Refractory Bladder Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Aug 2007
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Aug 2007
Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Biopharmaceuticals
 HSMN NewsFeed - 8 Aug 2007
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2007
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 2 Aug 2007
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2007
Axcan Pharma Submits Complete New Drug Application for ULTRASE
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 31 Jul 2007
Lev Pharmaceuticals Submits Biologics License Application for Cinryze(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jul 2007
Positive Aggrastat(R) Results Versus Integrilin(R) Featured in American Heart Journal
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 25 Jul 2007
Kuvan Receives Priority Review Status from FDA
Biopharmaceuticals
 HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 18 Jul 2007
FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 27 Jun 2007
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Jun 2007
FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2007
Lev Pharmaceuticals, Inc. Announces Completion of Marketing and Sales Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Dmitry Samarsky, Ph.D., as Vice President of Technology Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2007
Medical University of South Carolina Initiates New Trial of Cotara(R) in Brain Cancer Patients
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 25 Jun 2007
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
BioMarin Initiates Expanded Access Program for Kuvan in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2007
Genmab Announces Development Plans for Ofatumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Cephalosporin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jun 2007
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2007
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2007
Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonacept) for Treatment of CAPS
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
INNOVIVE Pharmaceuticals Receives FDA Fast Track Designation for Tamibarotene for the Treatment of Acute Promyelocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jun 2007
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2007
OVArian TUmor REsponse ('OVATURE') Trial Enrolls First U.S. Patient
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
Dendreon Announces FDA Confirms Data Required for Provenge(R) Licensure
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2007
CytRx Names Shi Chung Ng, Ph.D., Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2007
CytRx Provides Operational Update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 May 2007
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 May 2007
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 May 2007
Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 9 May 2007
Dendreon Receives Complete Response Letter From FDA for Provenge(R) Biologics License Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 May 2007
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 May 2007
Nabi Biopharmaceuticals Announces Positive Results of Phase IIb Trial of NicVAX
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 26 Apr 2007
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2007
Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Apr 2007
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 18 Apr 2007
Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Biopharmacetuicals
 HSMN NewsFeed - 16 Apr 2007
FDA Approves Fast Track Designation for Naryx Pharma's Product for Chronic Sinusitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Apr 2007
Aeris Therapeutics Strengthens Management Team
Devices Drug Delivery Personnel
 HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
Cell Therapeutics, Inc. (CTI) Announces XYOTAX(TM) Has Fast Track Designation for Women With Advanced Lung Cancer Who Are Performance Status 2 (PS2)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Amarin Appoints Declan Doogan to New Position of President-Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2007
Amarin Appoints Paul F. Duffy to New Position of President - U.S. Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2007
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Mar 2007
Northfield Laboratories Names New Vice President Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2007
Protox Announces Senior Management Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Mar 2007
Nuvelo Receives FDA Fast Track Status for rNAPc2 in Both First- and Second-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2007
KAI Pharmaceuticals Presents Encouraging Phase 1/2 Results of a Novel Treatment for Heart Attack
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Mar 2007
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Mar 2007
Napo Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer In HIV/AIDS Diarrhea Assessment
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2007
Amarin Expands Neurology Pipeline With Epilepsy Product Candidate
Biopharmaceuticals Drug Delivery Neurology Licensing
 HSMN NewsFeed - 27 Feb 2007
Amarin Appoints Professor William Hall as Non-Executive Director
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2007
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2007
GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2007
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Feb 2007
Amarin Announces Completion of Two Phase III Trials With Miraxion in Huntington's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Sequella Receives FDA Fast Track Status for TB Drug
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2007
Peregrine Pharmaceuticals' Tumor Necrosis Therapy Product for the Treatment of Lung Cancer Launched in China
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jan 2007
IRX Therapeutics Names John W. Hadden II President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2007
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jan 2007
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 8 Jan 2007
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in Patients With Peripheral T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2007
Xytis Pharmaceuticals Names Dr. Vincent F. Simmon President, Chief Executive Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2007
Gentium Acquires Italian Defibrotide Marketing Rights from Crinos
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2006
Pharmacyclics Submits New Drug Application for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2006
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
Northfield Laboratories Reports Preliminary Top-Line Data in Pivotal Phase III Trauma Study
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
FDA Grants Torisel NDA Priority Review Status
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Orphan Therapeutics Announces Rolling NDA Submission for LUCASSIN(TM) (terlipressin) to Treat Type 1 Hepatorenal Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Dec 2006
GPC Biotech Responds to Arbitration Claim by Spectrum Pharmaceuticals
Biopharmaceuticals Licensing Litigation
 HSMN NewsFeed - 12 Dec 2006
Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 7 Dec 2006
Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma; Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 15 Nov 2006
Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2006
Medicure Announces New AGGRASTAT(R) Data at 2006 Scientific Sessions of the American Heart Association
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 8 Nov 2006
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2006
Roche Advances Oral Polymerase Inhibitor into Phase II Study in Patients with Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
Peregrine Receives Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 12 Oct 2006
Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
Medicure Announces Launch of U.S. Sales Organization
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Oct 2006
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2006
ActivBiotics, Inc. Announces Completion of Patient Enrollment in Phase III Clinical Trial in Peripheral Arterial Disease
Biopharmaceuticals
 HSMN NewsFeed - 24 Sep 2006
Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2006
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Sep 2006
Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 20 Sep 2006
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2006
European Commission Grants Orphan Medicinal Product Designation to Nektar's Amphotericin B Inhalation Powder (ABIP) for the Prevention of Pulmonary Fungal Infections in Patients Deemed At Risk
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 18 Sep 2006
NEOPHARM Presents Updated CINTREDEKIN BESUDOTOX Phase I/II Median Survival Data at European Association of Neuro-Oncology (EANO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
Icagen Reports Results of Data Monitoring Committee Meeting in Phase III Assert Trial of ICA-17043
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 307

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 307 additional stories matching:
fast track designation
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.